Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 2/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870695 | 0.90 | TDP1 (0.59) | ATMTDP1MPOALDH1A1MAPT | |
| SCHEMBL4086162 | 0.89 | ATM (0.53) | ATMTDP1MPOALDH1A1MAPT | |
| SCHEMBL2891144 | 0.83 | TDP1 (0.58) | ATMTDP1MPOALDH1A1MAPT | |
| SCHEMBL1170113 | 0.83 | ATM (0.50) | ATMTDP1MPOALDH1A1MAPT | |
| SCHEMBL3633360 | 0.81 | MEN1 (0.39) | ATMTDP1MPOALDH1A1MAPT | |
| SCHEMBL3636229 | 0.81 | KAT2B (0.57) | KAT2B | |
| SCHEMBL27780316 | 0.80 | TDP1 (0.55) | ATMTDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL6489968 | 0.80 | ATM (0.55) | ATMTDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL311445 | 0.80 | ATM (0.55) | ATMTDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL5194061 | 0.80 | TDP1 (0.55) | ATMTDP1ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-2005177-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | Tibotec Pharmaceuticals Ltd. (IE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | ATM 3478/4885TDP1 1839/4885MPO 417/4885 |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | C1QBP, CD4, CHRM4 | ATM 4539/4885TDP1 2859/4885MPO 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.